Alv B

01/08/2025

We’re thrilled to welcome two outstanding additions to the Alv B team!

Gry Stensrud joins us as Chief Technical Officer. With a Ph.D. in Pharmaceutical Technology and 25+ years in biotech, pharma, and med tech, Gry brings deep expertise from companies like GE Healthcare, Photocure, and Lytix Biopharma — spanning CMC, quality, and pharmaceutical development from preclinical to commercial scale.

Anja Holm comes onboard as Head of Regulatory Affairs. A trained veterinarian from the University of Copenhagen, Anja has nearly 25 years’ experience in veterinary regulatory affairs, including 12 years in the CVMP at the European Medicines Agency, where she also served as Chair.

With Gry and Anja, we’re strengthening our cross-disciplinary expertise and our position in health tech and biotech.

Welcome to Alv B, Gry Stensrud and Anja E. H. Holm! We are excited to have you with us! 🚀

07/06/2023

Lovely article from forskning.no detailing how our research has been brought to life in the clinic. Together with our veterinarian partners at NMBU, the article highlights the first two dogs who have undergone our innovative treatment protocol for lung metastasis, including Misty, an 11-year old Maltese/Shih tzu mix who travelled with her owner all the way from the Netherlands to receive treatment. The good news is that CT confirms partial remission and stabilisation of an otherwise aggressive disease. Read more in the article below (in Norwegian) about Misty's story and the work we’re doing in clinic to improve cancer care in dogs.

https://lnkd.in/d9JeAHJN

Mark Klaver har reist fra Nederland til Ås fem ganger for at hunden Misty (12) skal få en ny immunterapi mot kreft. Misty er med i et utprøvende forsøk ved Veterinærhøgskolen som kan forlenge hunders liv.

14/04/2023

Say hello to Joy, the first dog to undergo our innovative treatment protocol. Joy is an 11 year old cocker spaniel, who was sadly diagnosed with breast (mammary) cancer which spread to her lungs. Alv B, together with our dedicated veterinary partners at NMBU, are hopeful we can improve the length and quality of her life.

20/03/2023

Folkeinvest gratulerer Alv B med vellykket kapitalinnhenting på 9,3 MNOK.

Alv B utvikler kreftbehandling for hund, med direkte overføringsverdi til humanmedisin. Planlagt børsnotering i 2024.

Innhentet kapital skal finansiere videre kommersialisering i 2023.

31/01/2023

Like humans, dogs can also develop aggressive cancers in the head and neck, and can hugely decrease the quality of life for our beloved companions; impacting the dog’s ability to eat, smell or even see. At Alv B AS, we are committed to developing novel therapies for these hard-to-treat cancers. With our team of dedicated scientists and veterinarians, we are developing the next generation of immunotherapies to improve cancer care in dogs, ultimately giving them a better quality of life and allowing them to be a loved member of the family for longer.

Like humans, dogs can also develop aggressive cancers in the head and neck, and can hugely decrease the quality of life for our beloved companions; impacting…

25/01/2023

Alv B nevnes i et kjempeflott innslag fra veterinær Geir Erik Berge om fremskritt innenfor immunterapi, og bruken av hund som modell for human kreft. Innslaget går over to segmenter.

Så frø i snø Når snøen ligger som et teppe i hagen og blomsterkassene er bånnfryst, virker våren så veldig langt unna. Men det er fullt mulig å sysle litt i hagen selvom det er vinter. Man kan faktisk så selvom det er snø. Mauds gullkjole Dronning Maud hatet oppmerksomheten under kroninge...

10/01/2023

We’ve just became the #1 most followed startup on Folkeinvest! If you want to find out why people are so interested in Alv B, click the link below to register your interest and be notified when the campaign opens.

Revolusjonerende kreftbehandling for hund, med direkte overføringsverdi til humanmedisin. Meget gode resultater. Kommersialisering i 23, børs i 24

04/01/2023

(English: bottom of post)

Vi inviterer nysgjerrige, potensielle investorer og eksisterende aksjonærer til et uformelt informasjonsmøte om Alv B, 11 januar på Teams eller i Forskningsparken.

Påmelding via registreringsskjema: https://lnkd.in/ddTBCpxB

The presentation is mainly in Norwegian, but if you would like an English language presentation, please get in touch.

https://www.linkedin.com/posts/alv-b-as_english-bottom-of-post-vi-inviterer-nysgjerrige-activity-7016405649555132417-m7xj?utm_source=share&utm_medium=member_desktop

16/12/2022

Vi lanserer vår investeringskampanje i januar. Hvis du er interessert i banebrytende immunterapi for hund og menneske, registrer deg for å bli varslet når kampanjen åpner. Eller ta kontakt direkte for en tyvtitt på investeringstilbudet.
--
We are launching our fundraising campaign in January. If you are looking to support and invest in life-saving immunotherapy for dogs and humans, get notified when the campaign opens by following the link below. Or get a sneak peek at the pitch by contacting us directly.

https://lnkd.in/dsSwxtuS

Revolusjonerende kreftbehandling for hund, med direkte overføringsverdi til humanmedisin. Meget gode resultater. Kommersialisering i 23, børs i 24

12/12/2022

Vi rekrutterer nå firbeinte pasienter med lungemetastase for behandling med en av våre protokoller ved NMBU.

We are now recruiting canine patients with lung metastasis for treatment with one of our protocols at the Norwegian Life Science University.

Vi rekrutterer nå firbeinte pasienter med lungemetastase for behandling med en av våre protokoller ved NMBU. / We are now recruiting canine patients with lung…

30/11/2022

Today, to mark the end of Pet Cancer Awareness Month, we have received approval from The Norwegian Food Safety Authority (Mattilsynet) to test our Alvacan 4000 immune cell-based vaccine on privately owned dogs with cancer. The approval means that the planned phase I clinical trial can now garner data on the safety and efficacy of our vaccines, with our major goal to improve both the quality of life and life expectancy of dogs with cancer. This likely represents one of the largest studies of its kind.

Read more below....
https://lnkd.in/d3ZVpviY

Alv B receives approval for cancer study in dogs.

29/11/2022

Alv B AS files for patent protection on cancer vaccine technology.

Today, we have filed for patent protection for our innovative cancer vaccine technology. In cooperation with the patent attorney office, Potter Clarkson, we have submitted our application at the United Kingdom patent office for protection towards the development, manufacturing and sale of ALAVCAN-DC products.

The technology we are protecting can create cancer vaccines quicker and cheaper than standard DC vaccine protocols published to date, while also resulting in 50x higher cytokine secretion compared to reference protocols, during our preliminary laboratory tests.

This marks a milestone for Alv B and brings us one step closer to market and to improving cancer care in dogs and humans globally.

Read more below…
https://lnkd.in/dfh9QXiK